OLX 301A
Alternative Names: OLX-10212; OLX-301A; OLX301A NLatest Information Update: 28 Feb 2026
At a glance
- Originator OliX Pharmaceuticals
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry age-related macular degeneration; Wet age-related macular degeneration
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for phase-I development in Dry age-related macular degeneration in USA (Intravitreous, Injection)
- 28 Feb 2026 No recent reports of development identified for phase-I development in Wet age-related macular degeneration in USA (Intravitreous, Injection)
- 10 Nov 2025 Olix Pharmaceuticals completes a phase I trial in Wet age-related macular degeneration and Dry age-related macular degeneration in USA (Ophthalmic) (NCT05643118)